Apixaban Dosing in Renal Impairment
For atrial fibrillation patients with renal impairment, use apixaban 2.5 mg twice daily ONLY if the patient meets at least TWO of three specific criteria: age ≥80 years, body weight ≤60 kg, OR serum creatinine ≥1.5 mg/dL (133 μmol/L); otherwise, use the standard 5 mg twice daily dose regardless of renal function. 12
Dosing Algorithm for Atrial Fibrillation
The FDA-approved dosing strategy differs fundamentally from a simple creatinine clearance-based approach:
Standard Dose: 5 mg twice daily
Use this dose for ALL patients UNLESS they meet the dose reduction criteria below 12
Reduced Dose: 2.5 mg twice daily
Reduce dose ONLY when at least 2 of these 3 criteria are present:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Critical point: A single criterion (including isolated renal impairment) does NOT warrant dose reduction 12
End-Stage Renal Disease on Dialysis
For ESRD patients on hemodialysis, the FDA label states that standard dosing (following the above criteria) results in apixaban concentrations similar to those in the pivotal ARISTOTLE trial 22. However, clinical efficacy and safety data in dialysis patients are limited, as these patients were excluded from major trials 2.
Evidence Supporting This Approach
The 2024 ESC Guidelines explicitly warn against arbitrary DOAC dose reductions, stating that reduced dosing should occur only when patients meet DOAC-specific criteria to prevent underdosing and avoidable thromboembolic events 1. This is critical because:
- Real-world data show that apixaban 5 mg in patients with severe CKD (stage 4/5) was associated with higher bleeding risk compared to 2.5 mg, but no difference in stroke/systemic embolism or mortality 3
- Dose-adjusted apixaban concentrations are approximately 3.3-fold higher in patients with CrCl <30 mL/min compared to normal renal function 4
- Patients with moderate renal impairment (CrCl 30-60 mL/min) on standard 5 mg dosing had roughly twice the drug exposure compared to those with normal renal function 5
Dosing for VTE Treatment/Prophylaxis
For deep vein thrombosis, pulmonary embolism, or VTE prophylaxis post-orthopedic surgery, no dose adjustment is recommended based on renal function alone 2. The standard regimens apply:
- VTE treatment: 10 mg twice daily for 7 days, then 5 mg twice daily
- VTE prophylaxis (post-hip/knee surgery): 2.5 mg twice daily
However, emerging evidence suggests that in severe renal disease (CrCl <25 mL/min or dialysis), reduced-dose apixaban (2.5 mg twice daily) for VTE treatment may have significantly lower bleeding rates (3.8% vs 14.4%) with similar VTE recurrence rates compared to standard dosing 6. This represents an off-label consideration when balancing bleeding risk in this high-risk population.
Key Pharmacokinetic Considerations
Apixaban has 27% renal elimination 22, making it less dependent on renal clearance than other DOACs like dabigatran (80% renal) or edoxaban (50% renal) 7. Despite this, renal impairment significantly impacts apixaban exposure:
- In ESRD patients post-dialysis, systemic exposure is 36% higher than in patients with normal renal function 22
- Dialysis removes minimal apixaban (clearance ~18 mL/min), with only 14% lower exposure on-dialysis versus off-dialysis 22
Common Pitfalls to Avoid
Do not reduce apixaban dose based solely on CrCl or eGFR - This contradicts FDA labeling and may lead to underdosing and stroke risk 12
Do not use the European Medicines Agency criteria - The EMA recommends dose reduction for CrCl 15-29 mL/min, but FDA labeling (which should guide U.S. practice) uses the three-criteria approach 12
Avoid underdosing in moderate CKD - Patients with CrCl 30-60 mL/min should receive 5 mg twice daily unless they meet 2 of 3 dose-reduction criteria 12
Monitor patients with severe CKD closely - While standard dosing may be appropriate per FDA criteria, these patients have substantially higher drug exposure and bleeding risk 453